For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed at $458.28 up 0.31% from its previous closing price of $456.87. In other words, the price has increased by $0.31 from its previous closing price. On the day, 1.32 million shares were traded. ALNY stock price reached its highest trading level at $462.88 during the session, while it also had its lowest trading level at $451.045.
Ratios:
For a deeper understanding of Alnylam Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 10.93 whereas as Long-Term Debt/Eq ratio is at 10.36.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 19 ’25 when Garg Pushkal sold 1,455 shares for $458.41 per share. The transaction valued at 666,987 led to the insider holds 20,221 shares of the business.
Garg Pushkal sold 1,396 shares of ALNY for $632,759 on Aug 18 ’25. The EVP Chief R&D now owns 21,676 shares after completing the transaction at $453.27 per share. On Aug 18 ’25, another insider, Tanguler Tolga, who serves as the EVP, Chief Commercial Officer of the company, sold 1,396 shares for $453.27 each. As a result, the insider received 632,759 and left with 29,466 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 60070883328 and an Enterprise Value of 59953041408. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.40 while its Price-to-Book (P/B) ratio in mrq is 239.53. Its current Enterprise Value per Revenue stands at 24.352 whereas that against EBITDA is -484.716.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.32, which has changed by 0.64158034 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $457.92, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is 30.75%, while the 200-Day Moving Average is calculated to be 62.82%.
Shares Statistics:
For the past three months, ALNY has traded an average of 1.05M shares per day and 1273390 over the past ten days. A total of 130.98M shares are outstanding, with a floating share count of 125.53M. Insiders hold about 4.23% of the company’s shares, while institutions hold 97.89% stake in the company. Shares short for ALNY as of 1753920000 were 3238527 with a Short Ratio of 3.10, compared to 1751241600 on 3327381. Therefore, it implies a Short% of Shares Outstanding of 3238527 and a Short% of Float of 3.26.
Earnings Estimates
The current rating of Alnylam Pharmaceuticals Inc (ALNY) is the result of assessments by 14.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $2.25, with high estimates of $4.34 and low estimates of $0.68.
Analysts are recommending an EPS of between $6.54 and $2.88 for the fiscal current year, implying an average EPS of $3.92. EPS for the following year is $9.17, with 17.0 analysts recommending between $19.87 and $4.15.
Revenue Estimates
A total of 24 analysts believe the company’s revenue will be $942.7M this quarter.It ranges from a high estimate of $1.27B to a low estimate of $805M. As of the current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $500.92MFor the next quarter, 24 analysts are estimating revenue of $1.2B. There is a high estimate of $1.33B for the next quarter, whereas the lowest estimate is $928.13M.
A total of 28 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $3.82B, while the lowest revenue estimate was $3.39B, resulting in an average revenue estimate of $3.5B. In the same quarter a year ago, actual revenue was $2.25BBased on 29 analysts’ estimates, the company’s revenue will be $4.83B in the next fiscal year. The high estimate is $7.61B and the low estimate is $2.81B.
